Nitrase Therapeutics

Nitrase Therapeutics

  • Founded: 2012
  • Location: Brisbane, CA
  • Employee range: 1 - 10
  • Clinical stage: RD
  • Therapy area: Parkinson's
  • Drug types: NEU, ONC
  • Lead product: Undisclosed
  • Product link:
  • Funding: $38M A Apr 2020
  • Investors: Sofinnova, AbbVie Ventures

job board

Short description:

Nitration enzyme

Drug notes:

Also RD oncology

Long description:

Nitrase Therapeutics is developing drugs against newly discovered nitration enzymes. Nitration-dependent diseases include age-related conditions, such as neurodegeneration disease, fibrosis and cancer, however nitration has previously been an elusive area for drug development as it was thought to be a pure chemical reaction. Nitrase Therapeutics’ scientists were the first to identify the enzyme-dependent nature of nitration and are now using their unique NITROME platform to target these enzymes. By targeting these enzymes, Nitrase hopes to slow or halt the progression of diseases, with their lead indications including Parkinson’s disease and cancer.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy